|Bid||8.65 x 800|
|Ask||9.19 x 800|
|Day's Range||8.47 - 8.91|
|52 Week Range||2.50 - 10.30|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2021 - Mar 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
DEER PARK, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference from February 24th through February 26th. About Eton PharmaceuticalsEton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®, and has six additional products that have been submitted to the FDA.Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.Company Contact:David Krempadkrempa@etonpharma.com612-387-3740
With the business potentially at an important milestone, we thought we'd take a closer look at Eton Pharmaceuticals...
Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its neurology portfolio that includes lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101) product candidates, to Azurity Pharmaceuticals. The marketing applications for all three candidates are currently under review with the FDA. Azurity will be responsible for commercialization following regulatory approval, though Eton will support Azurity in the transition and through regulatory approval. "This transaction allows us to focus on growing our orphan drug business." We will no longer need to invest in a neurology sales force, which will significantly increase our profitability in 2021 and 2022." said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Last month, the company acquired Canadian rights to ALKINDI SPRINKLE from Diurnal Group plc. Eton currently commercializes ALKINDI SPRINKLE in the U.S. as replacement therapy for Adrenocortical Insufficiency in children under 17. Under the terms of the transaction, Eton will receive up to $45 million in payments from Azurity, including $15 million at closing, $15 million upon achievement of approval and product launch milestones, and the remaining $15 million upon achievement of commercial sales milestones. Besides, Eton is eligible to receive a single-digit percentage royalty on Azurity's products' net sales. Price Action: ETON gains 1.2% at $10 in premarket trading on the last check Monday. See more from BenzingaClick here for options trades from BenzingaVeru's COVID-19 Drug Candidate Shows High Relative Reduction In Treatment Failures, Mortality In Mid-Stage StudyAvrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.